Data on Brisdelle™ (Paroxetine) Capsules, the First and Only FDA-Approved Non-Hormonal Therapy for Moderate to Severe Vasomotor Symptoms Associated with Menopause, to be Presented at the 2013 Annual Meeting of The North American Menopause Society

Download image Noven Pharmaceuticals, Inc. (PRNewsFoto/Noven Pharmaceuticals, Inc.) MIAMI, Fla. and NEW YORK, N.Y., Oct. 2, 2013 /PRNewswire/ -- Noven Pharmaceuticals, Inc., today announced that 11 presentations, featuring data analyses from its Phase 3 pivotal trials that supported the recent U.S. Food and Drug Administration approval of Brisdelle™ (paroxetine capsules, 7.5 mg/day) for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause, will be showcased at the 2013 Annual Meeting of The North American Menopause Society (NAMS) in Dallas on Oct. 9-10. Brisdelle™ was specifically developed for and studied in women who experience...